Skip to main content

Table 1 Patient characteristics

From: Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Characteristic Patients with biomarker measurements Patients without biomarker measurements P value
ER positive and/or PR positive (n [%]) 85 (58%) 159 (62%) 0.45a
Prior adjuvant chemotherapy (n [%]) 98 (60%) 161 (56%) 0.31a
Objective response (complete or partial; n [%]) 38 (24%) 66 (23%) 0.88a
Median age (years) 54.9 57.2 0.25b
Median follow up (years) 8.3 8.5 0.77b
Median number of metastatic sites (n) 1 1 0.14b
Median disease-free survival (months) 19 31 0.0003b
Median time to progression (months) 4.1 4.3 0.62c
Median overall survival (months) 12.6 12.3 0.81c
  1. Note that data regarding hormone receptor status and prior adjuvant chemotherapy were not available for all patients enrolled in CALGB 9342, and the total number is therefore less than 469 for some of the comparisons. a P value is based on the test for comparing two proportions. b P value is based on the Wilcoxon rank-sum test for comparing median values. c P value is based on a comparison of Kaplan-Meier curves with the log-rank test.